News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA
Photo taken from Agenus/LinkedIn
May 17, 2024, 11:18

Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA

Agenus shared on LinkedIn:

“Today we announced that Agenus has been granted a Type B End-of-Phase 2 meeting from the U.S. FDA to discuss our botensilimab/balstilimab therapy for relapsed or refractory metastatic colorectal cancer.

Learn more.”

Source: Agenus/LinkedIn

Agenus Balstilimab botensilimab cancer FDA Metastatic colorectal cancer OncoDaily Oncology
Special Coverage
Blog
Dec 17, 2024, 23:36
Amol Akhade: Speaking for economics of precision oncology
Blog
Dec 17, 2024, 23:36
Scientific Achievements of Danish Cancer Institute in 2024
Science
Dec 17, 2024, 23:36
Sendurai Mani: The Power of Cancer Chimeras - A New Frontier in Cancer Research
Blog
Dec 17, 2024, 23:36
Cristian Massacesi: Working for a future where cancer is eliminated as a cause of death
Blog
Dec 17, 2024, 23:36
Richard Paxman: The road to scalp cooling reimbursement in the U.S.
Blog
Dec 17, 2024, 23:36
ESMO Ambassadors reporting on the latest Cancer Research in the past year from ESMO events
Blog
Dec 17, 2024, 23:36
Ravindran Kanesvaran: Evidence-based ESMO guidelines for Asian populations
Blog
Dec 17, 2024, 23:36
Durvalumab and chemotherapy improves survival in MIBC - Uro Today
Blog
Dec 17, 2024, 23:14
Gregory Maes: Great EACR Liquid Biopsies 2024 meeting
Blog
Dec 17, 2024, 23:14
Miriam Mutebi: Does Your Diet Affect Your Breast Health?
Science
Dec 17, 2024, 23:14
Stephen V Liu: Resistance and identification of synthetic lethal targets in KRAS STK11 NSCLC
Blog
Dec 17, 2024, 23:14
Elizabeth Ugwoma Awo-Ejeh: To the Heroes Behind the Scenes